Atomwise, which uses artificial intelligence to accelerate drug discovery for diseases like Ebola, multiple sclerosis, and leukemia, today announced the launch of its Artificial Intelligence Molecular Screen (AIMS) program. To date, it's backed by Data Collective, Khosla Ventures, DFJ, AME Cloud Ventures, Draper Associates, Y Combinator and OS Fund.